Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: P01BE03Orphan Medicine

Artesunate Amivas(artesunate)

Malaria

Marketing Authorisation Holder: Amivas Ireland Ltd

EMA Authorisation: 22/11/2021

INN: artesunate

Indication

Artesunate Amivas is indicated for the initial treatment of severe malaria in adults and children. Consideration should be given to official guidance on the appropriate use of antimalarial agents.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Artesunate Amivas — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.